What were the key takeaways from OPKO Health’s earnings call?

What guidance did OPKO Health's management provide for the next earnings period?

What factors drove the changes in OPKO Health's revenue and profit?

What is the revenue and EPS growth rate for OPKO Health year over year?

What is OPKO Health's gross profit margin?

What were the key takeaways from OPKO Health's earnings call?

Did OPKO Health beat or miss consensus estimates last quarter?

What does OPKO Health do and what are its main business segments?

- **Strategic Restructuring Success**: BioReference divestiture reduced costs, positioning for 2026 profitability with 4Kscore growth.
- **Therapeutic Pipeline Momentum**: 3 clinical-stage programs (EBV, MDX2001, MDX2004) and $1+ billion Regeneron collaboration.
- **Financial Strength**: $369M cash, $47M buybacks, and 2026 revenue guidance of $530-560M.
- **Key Catalysts**: Phase Ib MDX2001 trials, EBV Phase II decision, and CAR-T platform partnerships.

**【CEO Summary Section】**
- OPKO exited 2025 with momentum, completing the sale of BioReference's oncology division to focus on core clinical lab business and 4Kscore test. 
- ModeX pipeline advanced with 3 clinical programs (EBV vaccine, MDX2001, MDX2004) and a $1+ billion potential collaboration with Regeneron.
- Strong cash position ($369M) enabled $47M in share buybacks and R&D investments.

**【CFO Financial Commentary】**
- Q4 2025 total revenue: $148.5M (down 19% YoY due to asset sale). 
- Diagnostics revenue: $71.1M (down 31% YoY), with 4Kscore growing 16% to $7M.
- Pharmaceutical revenue: $77.4M (down 4% YoY), driven by Rayaldee and NGENLA.
- Operating loss: $38.3M (wider than 2024's $33.1M due to R&D investments).
- 2026 outlook: Revenue $530-560M, R&D spend $125-135M, and $113M remaining buyback authorization.

**【Q&A Key Highlights】**
- **MDX2001**: Phase Ia dosing complete (25+ patients), planning Phase Ib expansion for 2026. 
- **EBV Vaccine**: Merck evaluating Phase I data; Phase II targeting 2027 with $5M+ BARDA funding.
- **4Kscore**: 6% YoY growth in Q4, targeting primary care market with FDA label change.
- **Regeneron Collaboration**: $1+ billion milestone potential, with first candidates expected in 2026.
- **CAR-T Platform**: Late-stage preclinical work, seeking partners for clinical trials.
- **Profit Share Guidance**: Pfizer NGENLA gross profit share $34-37M in 2026, up from $12.5M in Q4 2025.

OPKO Health, Inc. (OPK) Q4 2025 Earnings Call Transcript

- **Strategic Divestiture Success**: $192.5M from oncology division sale, with $32.5M earn-out potential.
- **4Kscore Test Growth**: 20% Q3 volume increase, poised for accelerated growth with FDA label expansion.
- **Therapeutics Pipeline Expansion**: 4 candidates in clinical trials, including new MDX2004 immune rejuvenator.
- **Regeneron Collaboration**: $1B+ potential milestone payments for multispecific antibody programs.
- **2026 Outlook**: Diagnostics to reach breakeven in Q4 2025, Pharmaceuticals revenue growth 3-5%.

**【CEO Summary Section】**
- Completed sale of BioReference Health's oncology division for $192.5 million, with $32.5 million in earn-out potential.
- 4Kscore test volume grew 20% Q3 2025, driving clinical testing growth.
- Repurchased $25.1 million in shares YTD, with $126 million remaining under buyback program.
- Advanced 4 therapeutics into clinical trials, including MDX2001 (Phase I) and MDX2004 (new multispecific immune rejuvenator).
- Collaborated with Regeneron to develop multispecific antibodies targeting multiple pathways.
- BARDA-funded COVID antibody program to begin Phase I in early 2026.

**【CFO Financial Commentary】**
- Q3 2025 total revenue: $151.6 million (Diagnostics: $95.2M, Pharmaceuticals: $56.4M).
- Diagnostics operating income: $81.6 million (vs. $58.5M prior year), driven by cost savings and 4Kscore growth.
- Pharmaceuticals revenue up 8% Y/Y, with Rayaldee contributing $7.5 million (29% Y/Y growth).
- R&D expenses: $29.6 million, up 5% Y/Y, supporting ModeX pipeline.
- Q4 2025 guidance: Total revenue $135-140M, operating expenses $175-180M.
- 2026 outlook: Diagnostics revenue growth 1-3%, Pharmaceuticals 3-5%, Pfizer profit share $32-35M.

**【Q&A Key Highlights】**
- **MDX2001 Progress**: 5 patients at dose level 5, total enrollment ~30. Expansion cohorts expected in 2026.
- **4Kscore Growth**: Label expansion to primary care physicians could double addressable market. Q3 volume up 20% despite label change in mid-quarter.
- **Regeneron Collaboration**: 4 initial programs across oncology, immunology, and metabolism. Milestone payments could exceed $1B if successful.
- **COVID Antibody Program**: BARDA-funded Phase I to begin early 2026, targeting immunocompromised populations.
- **Financial Assumptions**: 2026 Diagnostics ASPs stable, volume growth 1-3%. Pfizer profit share expected $32-35M (vs. $8.8M in Q3 2025).

OPKO Health, Inc. (OPK) Q3 2025 Earnings Call Transcript

- **$225M Oncology Sale**: Labcorp transaction to close Q3, positioning BioReference for profitability with $300M core testing business.
- **12% 4Kscore Growth**: FDA expanded use approval to drive primary care doc adoption, with Q2 volume up 12% YoY.
- **$6.5M BARDA Funding**: Infectious disease programs supported by $30-35M annual target, advancing multi-specific antibody pipeline.
- **Cash Flow Breakeven**: Diagnostics to achieve post-closing, with $285M cash and $192.5M from sale expected in Q3.

**【CEO Opening Remarks】**
- Sold oncology assets to Labcorp for $225M, with $192.5M at closing and up to $32.5M earn-out. Remaining BioReference focuses on core testing (urology, clinical services) with 2024 revenue of $300M.
- $200M stock buyback program ($141.5M remaining) to maximize shareholder value. R&D investments partially funded by partners (e.g., BARDA: $59M in 2024, $51M YTD 2025).

**【BioReference Update】**
- Restructuring: 1,900 headcount in Q2, expected 1,450-1,500 post-closing. Annualized cost savings of $25M+; Q2 operating loss $18.2M (vs. $26.6M in 2024).
- 4Kscore test volume up 12% YoY; FDA approved expanded use without digital rectal exam, targeting primary care docs.
- Non-oncology revenue growth 1.4% YoY; 4Kscore revenue acceleration in Q2 and July.

**【Pharmaceutical Business】**
- NGENLA: $6.1M profit share in Q2; 1/3 global long-acting hGH market share. Pfizer commercialization efforts to drive adoption.
- OPK-88006: Preclinical data superior to semaglutide for MASH; oral formulation with Entera Bio in pre-IND stage.
- BARDA funding: $6.5M in Q2, $30-35M annual target for infectious disease programs.

**【Financial Results】**
- Q2 2025: Total revenue $156.8M (Diagnostics $101.1M, Pharma $55.7M). Operating loss $60M (vs. $61.7M in 2024). Net loss $148.4M due to convertible note exchange ($92M expense).
- Cash: $285M as of Q2; $192.5M from Labcorp sale expected in Q3, with potential $225M total.
- 2025 Outlook: Revenue $640-660M; Diagnostics to reach cash flow breakeven post-closing.

**【Q&A Highlights】**
- 4Kscore: FDA approval to expand use, 12% YoY growth, and July acceleration; primary care doc adoption expected to drive further growth.
- Obesity treatment: Dual GLP-1/glucagon agonist (OPK-88006) targets MASH; oral formulation with Entera Bio in pre-IND stage.
- Capital allocation: Buybacks ($141.5M remaining), R&D investments, and strategic partnerships to fund pipeline.

OPKO Health, Inc. (OPK) Q2 2025 Earnings Call Transcript

- **$225M oncology sale**: Divests low-margin business, focuses on profitable core diagnostics. 
- **$100M buyback**: Signals confidence in undervalued shares. 
- **14.5% 4Kscore growth**: Core diagnostic franchise remains strong. 
- **$110M BARDA funding**: Supports advanced antibody development. 
- **Q1 2025 net loss**: Improved 17% YoY to $67.6M, driven by cost savings.

**【CEO Opening Remarks】**
- Sold BioReference's oncology business to LabCorp for up to $225M, retaining core clinical testing operations ($320M annual revenue). 
- Announced $100M stock buyback (total $200M authorized) and note exchange to strengthen capital structure.
- Highlighted progress in pharmaceutical pipeline (OPK-88006, MDX2001) and Latin American/EirGen growth.

**【Elias Zerhouni - BioReference Update】**
- Q1 2025: BioReference revenue $102.8M (down 16% YoY due to LabCorp transaction). 
- Achieved $19M annualized cost savings (7% workforce reduction to 1,962). 
- 4Kscore test grew 14.5% YoY; oncology divestiture expected to close Q3 2025. 
- Pharmaceutical pipeline: 
  - OPK-88006 (GLP-1/glucagon agonist) in pre-IND; oral tablet collaboration with Entera Bio. 
  - MDX2001 (tetraspecific antibody) in Phase I; BARDA funding increased to $110M. 

**【Adam Logal - Financial Results】**
- Q1 2025: Net loss $67.6M (-17% YoY). 
- Diagnostics: Revenue $102.8M (down 19% YoY); operating loss $23.9M (improved 25% YoY). 
- Pharmaceuticals: Revenue $47.1M (flat YoY); R&D expenses $30.2M (43% YoY increase). 
- Full year 2025 guidance: 
  - Total revenue $675-685M. 
  - Costs & expenses $825-875M (includes $10-14M restructuring). 
  - R&D spend $120-130M (BARDA funding $37-43M). 

**【Q&A Highlights】**
- **NGENLA dynamics**: Pfizer facing commercial headwinds, but franchise growth continues. 
- **GLP-1/Glucagon tablet**: IND expected Q4 2025, Phase I results by end-2026. 
- **BARDA funding**: $110M committed, $95M contingent on milestones. 
- **Share buyback**: $159M remaining capacity (~14% of outstanding shares). 
- **Tariffs impact**: Minimal on U.S. operations, monitoring global supply chain.

OPKO Health (OPK)-30 Apr 25-2025 Q1 Earnings call transcript

- **ModeX Pipeline Acceleration**: 2 Phase 1 trials launched; EBV vaccine Phase 1 data expected Q2 2025. 
- **Financial Strength**: $495M cash; $100M buyback program. 
- **BioReference Turnaround**: Q4 testing volume +1%; on track for Q1 2025 breakeven. 
- **BARDA Support**: $205M potential funding for COVID/flu programs. 
- **Rayaldee China Launch**: Nicoya anticipates 2025 commercialization. 
- **R&D Intensity**: 2025 R&D spend $120-140M; BARDA offsets 33% of costs.

**【CEO Opening Remarks】**
- 2024 was transformative with ModeX pipeline advancing: 2 programs entered Phase 1 clinical trials (multispecific antibody and nanoparticle vaccine). 
- OPKO-88006 dual-GLP-1 glucagon agonist shows promising preclinical data; both subcutaneous and oral forms expected IND-ready by end-2025. 
- Pfizer's NGENLA sales growing in 42 countries; China partner Nicoya anticipates strong Rayaldee launch in 2025. 
- Financially strong with $495M cash; $100M allocated for stock/convertible note buybacks.

**【Elias Zerhouni - Pharmaceuticals & BioReference】**
- **ModeX Pipeline Progress**: 
  - MDX-2201 EBV vaccine (w/Merck) Phase 1 trial enrolling 200 adults; $50M upfront + $860M milestones. 
  - MDX-2001 tetraspecific antibody Phase 1a safety/immunogenicity trial at 4 sites; 45 patients with solid tumors. 
  - MDX-2301 anti-COVID antibody IND-targeting Q4 2025. 
- **BARDA Funding**: $51M supplement for COVID/flu programs; total potential $205M if milestones met. 
- **BioReference Restructuring**: 
  - Workforce reduced to 2,000 from 3,300; Q4 2024 testing volume up 1% vs. 2023. 
  - Oncology segment +5% net revenue; 4Kscore urology test volume +16%. 
  - Ex-US pharma sales +9% vs. 2023; Rayaldee sales stable with new dialysis delay evidence.

**【Adam Logal - Financial Results】**
- **Q4 2024 Highlights**: 
  - Total revenue $183.6M vs. $181.9M; net income $14M vs. loss $66.5M. 
  - Pharmaceuticals segment revenue $80.5M (+40% YoY); Diagnostics $103.1M (-16% YoY). 
  - Operating loss $23.8M vs. $108.8M; R&D spend $29.8M (+64% YoY). 
- **2025 Guidance**: 
  - Revenue $675-700M; R&D $120-140M (BARDA offsets $40-48M). 
  - Target 2025 EBITDA >$50M; cash end-2025 ≥$300M. 
  - BioReference to reach breakeven Q1 2025 with $20M annualized cost savings.

**【Q&A Key Takeaways】**
- **BioReference Profitability**: Q1 2025 breakeven; $4-8M non-recurring Q1 costs. 
- **EBV Vaccine Milestones**: Phase 1 data Q2 2025; Phase 2 decision Q3. 
- **Dual Agonist Development**: Oral form (Entera Bio) targeting weekly dosing; INDs Q4 2025. 
- **BARDA Funding**: $40-48M 2025; $110M committed vs. $205M potential. 
- **HIV Antibody Update**: Second-gen MDX-2003 with 10x potency; partner discussions ongoing. 
- **MDX-2001 Enrollment**: No biomarker cutoff; targeting broad solid tumor types.

Actual											-0.09	0.05	0.04	0.05	0.05	-0.03	0.04	-0.11	-0.08	-0.14	-0.11	-0.11	-0.02	-0.03	-0.11	-0.09	-0.12	-0.01	0.03	0.01	-0.1	-0.19	0.03	-0.04
Forecast											-0.0875	-0.066	0.044	0.042	0.048	0.018	-0.01	-0.02	-0.056	0.008	-0.084	-0.1117	-0.0767	-0.0717	-0.1	-0.1	-0.0954	-0.095	-0.0933	-0.0933	-0.0686	-0.1133	-0.06	-0.0686
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-2.86%	+175.76%	-9.09%	+19.05%	+4.17%	-266.67%	+500.00%	-450.00%	-42.86%	-1850.00%	-30.95%	+1.52%	+73.92%	+58.16%	-10.00%	+10.00%	-25.79%	+89.47%	+132.15%	+110.72%	-45.77%	-67.70%	+150.00%	+41.69%

OPK

OPK fundamentals

OPK Q4 2025 Earnings

Earnings Call

You can ask Aime

OPK

OPK fundamentals

OPK Q4 2025 Earnings

Earnings Call

OPK Earnings Call Summary for Q4/20254:30 PM on Feb 26, 2026

OPK Earnings Call Summary for Q3/20254:30 PM on Oct 29, 2025

OPK Earnings Call Summary for Q2/20254:30 PM on Jul 31, 2025

OPK Earnings Call Summary for Q1/20254:30 PM on Apr 30, 2025

OPK Earnings Call Summary for Q4/20244:30 PM on Feb 27, 2025

You can ask Aime